Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
Beliebteste Broker
News
- 24.10. - 22:00 Uhr
Medicure Announces Positive Settlement of Product Development and Supply Contracts
WINNIPEG, MB / ACCESSWIRE / October 24, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that a product development and supply contract settlement between its subsidiaries Medicure International Inc. & Medicure Pharma Inc., and a third party has been reached. Medicure has received a payment of € 1.5 million as final settlement. » Mehr auf accesswire.com
- 14.08. - 21:30 Uhr
Medicure Announces Closing of Asset Purchase Agreement with Canam Bioresearch for Acquisition of Intellectual Property
WINNIPEG, MB / ACCESSWIRE / August 14, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce that, further to its news release on June 24, 2024, it has acquired certain intellectual property assets of CanAm Bioresearch Inc. ("CanAm") related to the discovery of new chemical entities that can be developed for therapeutic use, pursuant to an asset purchase agreement ("Agreement") dated June 24, 2024, the (the "Transaction"). As previously disclosed, Medicure believes that the new chemical entities hold promise to provide improvements over existing lead compounds in alignment with the treatment of diseases being targeted by Medicure, and could provide significant value upon completion of all required non-clinical and clinical studies and regulatory approval. » Mehr auf accesswire.com
- 14.08. - 21:00 Uhr
Medicure Reports Financial Results for Quarter Ended June 30, 2024
WINNIPEG, ON / ACCESSWIRE / August 14, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2024. Quarter Ended June 30, 2024 Highlights: Recorded total net revenue of $5.2 million during the quarter ended June 30, 2024 compared to $6.0 million for the quarter ended June 30, 2023 and; Recorded total net revenue from the sale of AGGRASTAT® of $1.8 million during the quarter ended June 30, 2024 compared to $2.6 million for the quarter ended June 30, 2023 and; Recorded total net revenue from the Marley Drug business of $2.7 million ($790,000 from sales of ZYPITAMAG®, and $1.9 million from other pharmacy revenue) during the quarter ended June 30, 2024 compared to $2.7 million ($600,000 from sales of ZYPITAMAG and $2.1 million from other pharmacy revenue) for the quarter ended June 30, 2023 and; Recorded total net revenue from the sale of ZYPITAMAG of $1.4 million ($654,000 through the insured business, and $790,000 through Marley Drug) during the quarter ended June 30, 2024 compared to $1.3 million ($722,000 through insured business and $600,000 through Marley Drug) for the quarter ended June 30, 2023 and; Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended June 30, 2024 was negative $514,000 compared to adjusted EBITDA of $948,000 for the quarter ended June 30, 2023 and; Net Loss for the quarter ended June 30, 2024 was $1.2 million or $0.12 per share compared to net income of $253,000 or $0.03 per share for the quarter ended June 30, 2023. » Mehr auf accesswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 3,52 Mio | 15,10% |
Bruttoeinkommen | 2,01 Mio | 28,57% |
Nettoeinkommen | 829,11k | 573,85% |
EBITDA | 378,79k | 162,52% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 6,09 Mio € |
Anzahl Aktien | 10,44 Mio |
52 Wochen-Hoch/Tief | 1,16 € - 0,58 € |
Dividenden | Nein |
Beta | 0,9 |
KGV (PE Ratio) | 3,47 |
KGWV (PEG Ratio) | 0,03 |
KBV (PB Ratio) | 0,47 |
KUV (PS Ratio) | 0,44 |
Unternehmensprofil
Medicure Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Erforschung, Entwicklung und Vermarktung von Humantherapien für den kardiovaskulären Markt in Kanada und den Vereinigten Staaten beschäftigt. Das Unternehmen vermarktet und vertreibt AGGRASTAT-Injektion, einen Glykoprotein-GP IIb/IIIa-Rezeptor-Antagonisten für die Behandlung des akuten Koronarsyndroms, einschließlich instabiler Angina pectoris und Nicht-Q-Wellen-Myokardinfarkt. Außerdem bietet es ZYPITAMAG zur Behandlung von Patienten mit primärer Hyperlipidämie oder gemischter Dyslipidämie an. Darüber hinaus bietet das Unternehmen ReDS an, ein nicht-invasives medizinisches Gerät, das die Messung von Lungenflüssigkeit für das Management von kongestiver Herzinsuffizienz ermöglicht. Darüber hinaus bietet das Unternehmen Natriumnitroprussid-Injektionen zur Senkung des Blutdrucks bei erwachsenen und pädiatrischen Patienten in hypertensiven Krisen sowie zur Erzeugung einer kontrollierten Hypotonie zur Verringerung von Blutungen bei Operationen und zur Behandlung von akuter Herzinsuffizienz an. Das Unternehmen bietet seine Produkte sowohl über den Apothekenhandel als auch online an. Das Unternehmen wurde 1997 gegründet und hat seinen Hauptsitz in Winnipeg, Kanada.
Name | Medicure |
CEO | Dr. Albert David Friesen Ph.D. |
Sitz | Winnipeg,
mb Australien |
Website | |
Industrie | Chemikalien |
Börsengang | 09.08.2018 |
Mitarbeiter | 0 |
Ticker Symbole
Börse | Symbol |
---|---|
Pnk | MCUJF |
Tsxv | MPH.V |
Frankfurt | NGQ1.F |
München | NGQ1.MU |
Assets entdecken
Shareholder von Medicure investieren auch in folgende Assets